Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 726,752
  • Shares Outstanding, K 239,063
  • Annual Sales, $ 332,310 K
  • Annual Income, $ -51,750 K
  • EBIT $ -29 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.11
  • Price/Sales 1.98
  • Price/Cash Flow 113.21
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 95.86% (-35.67%)
  • Historical Volatility 72.21%
  • IV Percentile 20%
  • IV Rank 3.56%
  • IV High 719.03% on 04/09/25
  • IV Low 72.85% on 03/18/25
  • Expected Move (DTE 10) 0.33 (12.28%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 4,033
  • Volume Avg (30-Day) 2,144
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 96,166
  • Open Int (30-Day) 91,402
  • Expected Range 2.37 to 3.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.23
  • Number of Estimates 4
  • High Estimate 0.38
  • Low Estimate 0.02
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +330.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.63 +2.47%
on 03/09/26
3.68 -26.73%
on 02/18/26
-0.69 (-20.35%)
since 02/10/26
3-Month
2.63 +2.47%
on 03/09/26
4.18 -35.33%
on 01/08/26
-1.13 (-29.50%)
since 12/10/25
52-Week
0.69 +289.89%
on 05/15/25
4.18 -35.33%
on 01/08/26
+1.12 (+70.89%)
since 03/10/25

Most Recent Stories

More News
Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Therapeutics: Q4 Earnings Snapshot

ESPR : 2.70 (-11.18%)
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025...

ESPR : 2.70 (-11.18%)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular...

ESPR : 2.70 (-11.18%)
KKR : 89.96 (-1.08%)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

–  Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular...

ESPR : 2.70 (-11.18%)
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March...

ESPR : 2.70 (-11.18%)
Esperion to Participate in The 2026 Citizens Life Sciences Conference

ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11,...

ESPR : 2.70 (-11.18%)
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves...

ESPR : 2.70 (-11.18%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under...

ESPR : 2.70 (-11.18%)
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million,...

ESPR : 2.70 (-11.18%)
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14,...

ESPR : 2.70 (-11.18%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 3.70
2nd Resistance Point 3.49
1st Resistance Point 3.09
Last Price 2.70
1st Support Level 2.48
2nd Support Level 2.27
3rd Support Level 1.87

See More

52-Week High 4.18
Fibonacci 61.8% 2.84
Last Price 2.70
Fibonacci 50% 2.43
Fibonacci 38.2% 2.02
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar